Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2023-10-30 Annual Report
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Amended Annual Report 104 pages 4.5MB
Annual Report Classification · 100% confidence The document is titled 'Amended Annual Report' and references the 'Annual Report 2023' for the fiscal year ended 30 June 2023. It includes detailed sections typical of an annual report such as Chairman's Letter, Review of Operations & Activities, Director's Report, Corporate Governance Statement, Financial Statements, and Independent Auditor's Report. The document is lengthy (15,000 characters) and contains substantive financial data and operational review, not just an announcement or summary. It also mentions amendments to the Independent Auditor's reports but explicitly states no changes to financial statements or other sections. This confirms it is the full Annual Report document, not just an announcement or certification. Therefore, the correct classification is Annual Report (10-K).
2023-10-30 English
Notice of Annual General Meeting/Proxy Form 50 pages 1.2MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting' and contains detailed information about the upcoming AGM of Imugene Limited, including date, location, resolutions to be voted on, voting exclusions, and procedural details. It includes agenda items such as receiving financial statements and reports, election of directors, approval of remuneration reports, and share option plans. There is no actual financial data or results presented, only the notice and agenda for the meeting. The document is about informing shareholders of the AGM and the business to be conducted there, which fits the definition of AGM Information (AGM-R).
2023-10-29 English
Imugene Phase 1 onCARlytics CD19 virus clinical trial opens 3 pages 162.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated 26 October 2023, describing the commencement of a Phase 1 clinical trial for their onCARlytics CD19 virus technology. It highlights the dosing of the first patient and details about the trial design and objectives. The content is a news release about a clinical trial milestone rather than a financial report, regulatory filing, or management discussion. It does not contain financial data, audit information, or governance details. It is not a report publication announcement since it is a substantive announcement about a clinical trial start. The document fits best into the category of a general regulatory announcement or company update that does not fit other specific categories, which corresponds to Regulatory Filings (RNS).
2023-10-25 English
Imugene B Cell & OV Platforms Featured at ESMO Congress 4 pages 189.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated 24 October 2023. It details the company's presentations at the ESMO Congress, including summaries of clinical and preclinical data related to their immunotherapy and oncolytic virotherapy platforms. The content focuses on scientific and clinical updates rather than financial results, management changes, or regulatory filings. The document is not a full financial report, earnings release, or management discussion. It is a public announcement of company activities and scientific presentations at a conference. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2023-10-23 English
Change of Director's Interest Notice - PH 3 pages 7.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares/options held before and after the change, nature of the change, and dates. This is a clear report of personal share transactions by a company director. The document length is 3844 characters, which is typical for such notices. There is no indication of financial results, management discussion, or other report types. Therefore, this document fits the definition of Director's Dealing (DIRS).
2023-10-11 English
Change of Director's Interest Notice - LC 2 pages 9.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director's Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, nature of the change, and dates. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It does not contain financial performance data, management discussion, or other report types. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is not a brief announcement or a certification but a formal notice of director's interest changes.
2023-10-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.